BRPI0416925A - biomarcadores para a eficácia de tratamento com análogo de somatostatina - Google Patents

biomarcadores para a eficácia de tratamento com análogo de somatostatina

Info

Publication number
BRPI0416925A
BRPI0416925A BRPI0416925-5A BRPI0416925A BRPI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A
Authority
BR
Brazil
Prior art keywords
pasireotide
biomarkers
igf
somatostatin
efficacy
Prior art date
Application number
BRPI0416925-5A
Other languages
English (en)
Inventor
Muriel Saulnier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416925A publication Critical patent/BRPI0416925A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

"BIOMARCADORES PARA A EFICáCIA DE TRATAMENTO COM ANáLOGO DE SOMATOSTATINA". Ensaios de expressão genética foram realizados usando tecidos de macacos tratados com o análogo de somatostatina pasireotide em uma dose subterapêutica por 14 dias. Os ensaios foram analisados para identificar os modos de ações de pasireotide com relação a aplicações terapêuticas. Os efeitos sobre os eixos do hormónio do crescimento /IGF-1 e glucagon /insulina foram refletidos nas alterações do nível de transcrito em vários órgãos. Os genes expressos são úteis como marcadores substituintes da atividade biológica de pasireotide especialmente os achados para IGF-2 na pituitária e rins.
BRPI0416925-5A 2003-11-25 2004-11-24 biomarcadores para a eficácia de tratamento com análogo de somatostatina BRPI0416925A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52507903P 2003-11-25 2003-11-25
PCT/EP2004/013350 WO2005053732A1 (en) 2003-11-25 2004-11-24 Biomarkers for the efficacy of somatostatin analogue treatment

Publications (1)

Publication Number Publication Date
BRPI0416925A true BRPI0416925A (pt) 2007-01-16

Family

ID=34652298

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416925-5A BRPI0416925A (pt) 2003-11-25 2004-11-24 biomarcadores para a eficácia de tratamento com análogo de somatostatina

Country Status (11)

Country Link
US (1) US20070275382A1 (pt)
EP (1) EP1689429A1 (pt)
JP (1) JP2007518702A (pt)
KR (1) KR20060118504A (pt)
CN (1) CN1905895A (pt)
AU (1) AU2004294269A1 (pt)
BR (1) BRPI0416925A (pt)
CA (1) CA2546448A1 (pt)
IL (1) IL175574A0 (pt)
MX (1) MXPA06005952A (pt)
WO (1) WO2005053732A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
ES2431573T3 (es) * 2007-12-03 2013-11-27 Italfarmaco S.P.A. Nuevos análogos no selectivos de somatostatina
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
WO2013151688A1 (en) * 2012-04-06 2013-10-10 Georgia Regents University Methods and compositions for using insulin-like growth factor binding protein 6 in treating and diagnosing diabetes
US11504373B2 (en) * 2017-12-18 2022-11-22 Yale University Compounds and compositions for treating fibrosis
CN110144412B (zh) * 2019-06-10 2022-08-19 西北农林科技大学 一种与南阳牛生长相关的cnv标记的检测方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216290T3 (es) * 1997-05-13 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x.
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
CA2443627A1 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors

Also Published As

Publication number Publication date
MXPA06005952A (es) 2006-07-06
EP1689429A1 (en) 2006-08-16
US20070275382A1 (en) 2007-11-29
KR20060118504A (ko) 2006-11-23
CN1905895A (zh) 2007-01-31
JP2007518702A (ja) 2007-07-12
WO2005053732A1 (en) 2005-06-16
IL175574A0 (en) 2006-09-05
CA2546448A1 (en) 2005-06-16
AU2004294269A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
Arnold et al. Angiogenesis in wound healing
Greenhalgh The role of growth factors in wound healing
Kasukonis et al. Codelivery of infusion decellularized skeletal muscle with minced muscle autografts improved recovery from volumetric muscle loss injury in a rat model
Vorotnikova et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo
BRPI0410963B8 (pt) anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
CN87101250A (zh) 伤口治疗
JP2015057431A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
Lepistö et al. Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat
ATE485825T1 (de) Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
Notodihardjo et al. A comparison of the wound healing process after the application of three dermal substitutes with or without basic fibroblast growth factor impregnation in diabetic mice
Himeda et al. Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
BRPI0410915A (pt) composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit
BRPI0416925A (pt) biomarcadores para a eficácia de tratamento com análogo de somatostatina
Frasch Dedifferentiation, redifferentiation, and transdifferentiation of striated muscles during regeneration and development
Melotti et al. Could cold plasma act synergistically with allogeneic mesenchymal stem cells to improve wound skin regeneration in a large size animal model?
Hwang et al. An effective range of polydeoxyribonucleotides is critical for wound healing quality
CN103097405A (zh) 用于伤口愈合的新型肽
Hirsch et al. Insulin‐like growth factor‐1 gene therapy and cell transplantation in diabetic wounds
CN105120884A (zh) 用于促进伤口愈合的短生物活性肽
Kwon et al. Synergic regenerative effects of polydeoxyribonucleotide and microcurrent on full-thickness rotator cuff healing in a rabbit model
BRPI0519330A2 (pt) Ácido nuclÉico isolado; vetor; cÉlula hospedeira; mÉtodo para expressar uma proteÍna; polipeptÍdeo isolado; cromoproteÍna isolada; oligonucleotÍdeo; mÉtodo para identificar um Ácido nuclÉico que codifica uma apoproteÍna de um enediina de nove membros contendo cromoproteÍna; cultura biologicamente pura de actinomadura sp. 21g792 (nrrl 30778); mÉtodo para preparar uma cromoproteÍna; mÉtodo para preparar uma cromoproteÍna modificada; mÉtodo para inibir a progressço de uma doenÇa neoplÁsica em um mamÍfero; composiÇço farmacÊutica; e composto
DE69331144D1 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere
US20090306219A1 (en) Topical use of plant extract for skin detoxification

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]